FDA Investigation Leads to Charges Against Two Indian Nationals Involved in Transnational Counterfeit Drug Distribution Scheme
- September 29th, 2026
- 8 views
Silver Spring, MD / CRWE PRESS RELEASE / September 29, 2026 - The U.S. Attorney’s Office for the Middle District of Florida and the Criminal Division of the U.S. Department of Justice today announced federal charges against Swapnadip Roy, 33, and Vicky Ramancha, 37, both Indian nationals. The two individuals have been charged with conspiracy and smuggling related to an alleged transnational counterfeit prescription drug distribution scheme. The U.S. Food and Drug Administration’s Office of Criminal Investigations assisted with this investigation.
“Infiltrating the American drug supply with counterfeit products isn’t just a crime — it’s also a direct threat to public health and patient safety,” said Acting FDA Commissioner of Food and Drugs, Kyle Diamantas, J.D. “The FDA will continue to trace illicit networks wherever they lead, across borders and through complex supply chains, to ensure that anyone who seeks to profit off counterfeit medicines face accountability — all in our mission to keep Americans safe.”
According to court documents, between July 2023 and April 2024, Roy and Ramancha allegedly obtained counterfeit Ozempic from unauthorized sources in China. The counterfeit Ozempic allegedly distributed by Roy, Ramancha, and their co-conspirators included counterfeit packaging, package inserts, pen labels, and needles meant to deceive downstream customers, including pharmacies and patients, into believing they were receiving authentic, manufacturer-authorized Ozempic. The indictment alleges that Roy, Ramancha, and their co-conspirators sold the counterfeit Ozempic to other co-conspirators and distributors in the U.S. at deeply discounted prices.
The FDA issued public safety alerts starting in December 2023 to warn consumers, pharmacies, and healthcare providers about counterfeit Ozempic products. Notably, court documents allege that Roy, Ramancha, and their co-conspirators continued distributing counterfeit Ozempic even after FDA’s December 2023 seizure and public warning.
The agency takes reports of possible counterfeit medicines seriously and works closely with other federal agencies and the private sector to help protect the nation’s drug supply. Entities, including online sellers, selling counterfeit and/or tampered medicines should be reported to the FDA. Suspected counterfeit products may be reported by going to Report a problem to the FDA.
An indictment is merely an allegation. All defendants are presumed innocent until proven guilty beyond a reasonable doubt in a court of law.
Media:
FDA Request for Comment
202-690-6343
Consumer:
888-INFO-FDA
###
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products.
Source: U.S. Food and Drug Administration (FDA)
Post Your Comments
Want To Find Some News?
Recent Posts
-
NJCP Completes Week 4 With Five Games in Four States
September 29th, 2026NJCP Football League Records 13 Results Through Three Weeks of 2026 Season
September 29th, 2026NJCP Football League Opens 2026 Season With Three Week 1 Matchups
September 29th, 2026September 28th, 2026What Wall Street Expects From Accenture, Acuity, and McCormick as Earnings Near
September 27th, 2026




Member Login